RIL AGM 2020: Reliance Industries likely to be a $400 billion company in three years, analysts say

Viram Shah of Vested Finance also said Jio has played a pivotal role in the acceleration of data adoption in the country.

Date: 15/7/2020

Billionaire Mukesh Ambani-led Reliance Industries (RIL) will create value for shareholders in coming years given the strategic partnerships with global tech giants, experts said after company's 43rd Annual General Meeting on July 15.

Reliance Industries share price more than doubled in a span of nearly four-months and hit a record high of Rs 1,978.50 today (before seeing some profit booking), taking the total market capitalisation to $167 billion (rupee/dollar rate at 75 a dollar) and entering in the top 60 most valued companies list globally.

Given the investment by global tech giants like Facebook, Google etc., and company's focus on Jio Platforms and Retail with digitalisation and advanced technology, experts feel the total value of Reliance Industries could be over $250 billion in the next 12 months and around $400 billion in three years down the line.

"I valued Reliance Industries at $200-210 billion now which soon become more than $250 billion," SP Tulsian of sptulsian.com told CNBC-TV18. "$70 billion to oil-to-chemical (O2C) business, $80 billion to Jio, $40-50 billion to Retail and $10-20 billion for investment and media businesses, which total comes to $200-210 billion," he explained.

He sees Reliance Industries in total a $400 billion company in three years down the line, with new tech business, Jio, Retail and hiving off O2C business. "I expect valuation of $170 billion for Jio and $100-150 billion for Retail."

Read Full article - Click Here

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

Similar to 2020, D-Street is at record high ahead of Budget 2021; will history repeat itself?

Experts are of the view that a repeat of 2020 or what happened in March might not be possible but some consolidation cannot be ruled out. Back in March when everyone wanted to write-off 2020 from their books, hope and liquidity supported markets and investor sentiment. Nobody thought that after touching a 3-year low in March 2020, benchmark indices would give double-digit returns by the end of the year. The S&P BSE Sensex and Nifty50 rallied by about 15 percent in 2020 and the big outperformance came from the small and midcap stocks. The rally is still continuing in 2021. The S&P BSE Sensex, which climbed Mount 49K, is up over 3 percent while the Nifty50 is up over 4 percent so far in January. Sensex scaling the 49,000-mark and Nifty50 touching 14,500 levels ahead of the Budget 2021 could make anyone cautious about the strength of the rally. Back in January 2020, both Sensex and Nifty touched fresh highs ahead of Budget, and then the market fell like a pack of cards. The ...

SD Solutions

Search This Blog